Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease

NCT02033941 is registered in ClinicalTrials.gov with Hillel Grossman as lead sponsor.

NCT NCT02033941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02033941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease
Lead sponsor
Hillel Grossman
Phase
Phase 2
Overall status
Terminated
Start date
July 3, 2018
Completion date
October 4, 2019
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease